Diagnosing diseases is basically the frontlines when it comes to fighting against illnesses and how effectively and efficiently this is done will affect how the rest of the battle goes. Unfortunately, diagnosis can be expensive, depending on the disease. Thanks to a new microchip, which can cost only $0.1 to create, this might not be a problem anymore.
The microchip in question was created by a team of engineers from Stanford who published their findings in the Proceedings of the National Academy of Sciences. Not only is the chip tiny, it’s also incredibly inexpensive to produce and can be manufactured at a large scale in a very short period of time.
“For the developing world, point-of-care (POC) diagnostics design must account for limited funds, modest public health infrastructure, and low power availability,” the paper reads. “To address these challenges, here we integrate microfluidics, electronics, and inkjet printing to build an ultra–low-cost, rapid, and miniaturized lab-on-a-chip (LOC) platform.”
Calling it the FNIP chip, the researchers created the device with three layers of varying expendability. As for how it is used, it’s basically a two-step process. First, the user would need to customize the configuration in order to suit the particular disease that needs to be diagnosed, Futurism reports. Next, the necessary samples for analysis can then be printed onto the top layer of the chip.
So, which diseases can this microchip detect? So far, the researchers tested it to analyze cancer fluid and succeeded. They also used it to diagnose immune cells and was able to pull off similar results as another diagnostic tool that would have cost $100,000 in comparison.
Before anyone gets too excited, however, the researchers are saying that it would take some time before the microchip becomes widely available. There are some hurdles to overcome first, including more tests to see if the platform is even safe to use.


Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Instagram Outage Disrupts Thousands of U.S. Users
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 



